Skip to main content

Advertisement

Table 4 Cost-benefit analysis of prophylaxis in respect to HBV reactivation by “Diagnosis Related Group” system in our 48 HBcAb positive HBsAg negative patients treated with Rituximab

From: Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma

  Unitary cost n. patients Total per patient Duration [days] Total
Cost of prophylaxis      
Lamivudine € 3,18 48 € 152,64 360 € 54.950,40
HBV DNA monitoring € 130,00 48 € 6.240,00 6 € 37.440,00
HBsAg monitoring € 17,00 48 € 816,00 6 € 4.896,00
AST/ALT monitoring € 5,74 48 € 275,52 12 € 3.306,24
Total € 155,92 48 € 7.484,16   € 100.592,64
Cost of HBV Reactivation      
HBV DNA monitoring € 130,00 48 € 6.240,00 6 € 37.440,00
AST/ALT monitoring € 5,74 48 € 275,52 12 € 3.306,24
Cost of DRG 205 [v24 Grouper] € 3.769,10 5 - - € 18.845,50
Total € 3.904,84 - - - € 40.746,24
  1. Drg 205: Liver disease except malignancies, cirrhosis, alcoholic hepatitis with cirrhosis.